| Year |
Citation |
Score |
| 2020 |
Kim KJ, Kim JW, Sung JH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Kim HK, Lee KW. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Scientific Reports. 10: 12308. PMID 32704014 DOI: 10.1038/S41598-020-68998-W |
0.325 |
|
| 2020 |
Lim SM, Kim SW, Cho BC, Kang JH, Ahn MJ, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, et al. Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 32599984 DOI: 10.4143/Crt.2020.245 |
0.343 |
|
| 2020 |
Han J, Ahn M, Kim S, Lee KH, Cho EK, Lee Y, Kim D, Kim J, Lee J, Lee G, Shim BY, Kim J, Chun SH, Lee SS, Min YJ, et al. ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI). Journal of Clinical Oncology. 38: 9601-9601. DOI: 10.1200/Jco.2020.38.15_Suppl.9601 |
0.319 |
|
| 2020 |
Lee KH, Ahn M, Han J, Kim S, Cho EK, Lee Y, Kim D, Kim J, Lee J, Lee G, Shim BY, Kim J, Chun SH, Lee SS, Min YJ, et al. Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study. Journal of Clinical Oncology. 38: 9572-9572. DOI: 10.1200/Jco.2020.38.15_Suppl.9572 |
0.3 |
|
| 2020 |
Kim S, Ahn M, Han J, Lee KH, Cho EK, Lee Y, Kim D, Kim J, Lee J, Lee G, Shim BY, Kim J, Chun SH, Lee SS, Min YJ, et al. Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study. Journal of Clinical Oncology. 38: 9571-9571. DOI: 10.1200/Jco.2020.38.15_Suppl.9571 |
0.301 |
|
| 2020 |
Ramalingam SS, Ciuleanu TE, Pluzanski A, Lee J, Schenker M, Caro RB, Lee KH, Zurawski B, Audigier-Valette C, Provencio M, Linardou H, Kim S, Borghaei H, Hellmann MD, O'Byrne KJ, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Journal of Clinical Oncology. 38: 9500-9500. DOI: 10.1200/Jco.2020.38.15_Suppl.9500 |
0.349 |
|
| 2020 |
Horn L, Liu SV, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, Carpeno JDC, Califano R, Nishio M, Orlandi F, Alexander JAA, Leal T, Cheng Y, Lee J, et al. Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC) Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct220 |
0.309 |
|
| 2019 |
Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Kim S, Yoon SS, ... Lee JS, et al. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Cells. 8. PMID 31795298 DOI: 10.3390/Cells8121538 |
0.312 |
|
| 2019 |
Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, et al. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer (Amsterdam, Netherlands). 135: 66-72. PMID 31447004 DOI: 10.1016/J.Lungcan.2019.07.007 |
0.342 |
|
| 2019 |
Segal NH, Wainberg ZA, Overman MJ, Ascierto PA, Arkenau H, Butler MO, Eder JP, Keilholz U, Kim D, Cunningham D, Khleif SN, Doucet L, Lee J, Nemunaitis JJ, Vaishampayan UN, et al. Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. Journal of Clinical Oncology. 37: 670-670. DOI: 10.1200/Jco.2019.37.4_Suppl.670 |
0.323 |
|
| 2019 |
Bang Y, Kaufman B, Geva R, Stemmer SM, Hong S, Lee J, Domchek SM, Lanasa MC, Tang M, Gresty C, Angell HK, Opincar LLM, Herbolsheimer PM, Evans TRJ. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer. Journal of Clinical Oncology. 37: 140-140. DOI: 10.1200/Jco.2019.37.4_Suppl.140 |
0.311 |
|
| 2019 |
Gutierrez M, Hellmann MD, Gubens M, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee J, Yang JC, Garon E, Basso AD, Ma H, Fong L, Snyder A, Yuan J, et al. Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct227 |
0.362 |
|
| 2019 |
Kim J, Kim K, Sung JH, Suh KJ, Lee JY, Kim SH, Kim JW, Lee J, Kim YJ, Bang S, Kim JH, Lee JS, Lee K. Abstract C074: Preclinical study of antitumor effect of alpelisib combined with paclitaxel in gastric caner Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C074 |
0.33 |
|
| 2018 |
Choi IS, Kim JH, Lee JH, Suh KJ, Lee JY, Kim JW, Kim SH, Kim JW, Lee JO, Kim YJ, Bang SM, Lee JS, Lee KW. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. Plos One. 13: e0205853. PMID 30346970 DOI: 10.1371/Journal.Pone.0205853 |
0.312 |
|
| 2018 |
Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Medical Journal. 59: 202-210. PMID 29436187 DOI: 10.3349/Ymj.2018.59.2.202 |
0.364 |
|
| 2017 |
Jung J, Lee H, Yun T, Lee E, Moon H, Joo J, Park WS, Choi M, Lee JO, Lee JS, Eom HS. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Oncotarget. 8: 74975-74986. PMID 29088839 DOI: 10.18632/Oncotarget.20480 |
0.3 |
|
| 2017 |
Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713701. PMID 28520527 DOI: 10.1200/Jco.2016.71.3701 |
0.347 |
|
| 2017 |
Cho BC, Ahn M, Lee J, Kim D, Kim S, John T, Kao SC, Goldman JW, Su W, Natale RB, Ahn JS, Kim H, Kim TM, Lin C, Overend P, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. Journal of Clinical Oncology. 35: 2069-2069. DOI: 10.1200/Jco.2017.35.15_Suppl.2069 |
0.344 |
|
| 2017 |
Yang JC, Cho BC, Kim D, Kim S, Lee J, Su W, John T, Kao SC, Natale R, Goldman JW, Overend P, Vishwanathan K, Ye X, Yang Z, Ahn M. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study. Journal of Clinical Oncology. 35: 2020-2020. DOI: 10.1200/Jco.2017.35.15_Suppl.2020 |
0.312 |
|
| 2017 |
Ahn M, Kim D, Cho BC, Kim S, Lee J, Ahn JS, Kim TM, Lin C, Kim H, John T, Kao SC, Goldman JW, Su W, Natale RB, Overend P, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. Journal of Clinical Oncology. 35: 2006-2006. DOI: 10.1200/Jco.2017.35.15_Suppl.2006 |
0.342 |
|
| 2017 |
Reckamp K, Lee J, Huang J, Proskorovsky I, Reichmann W, Krotneva M, Kerstein D, Huang H. Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts) Annals of Oncology. 28: ii38-ii39. DOI: 10.1093/Annonc/Mdx091.025 |
0.332 |
|
| 2017 |
Cho BC, Lim SM, Kim HR, Lee J, Lee K, Lee Y, Min YJ, Cho EK, Lee S, Shim HS, Chung J, Choi Y, Ahn M. MA07.07 Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study Journal of Thoracic Oncology. 12: S381-S382. DOI: 10.1016/J.Jtho.2016.11.430 |
0.302 |
|
| 2016 |
Chang H, Oh J, Zhang X, Kim YJ, Lee JH, Lee CT, Chung JH, Lee JS. EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy. Oncotargets and Therapy. 9: 5153-62. PMID 27578983 DOI: 10.2147/Ott.S107291 |
0.316 |
|
| 2016 |
Shin J, Lee JO, Choe JY, Bang SM, Lee JS. Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma (PEL-LL) in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 27283030 DOI: 10.4143/Crt.2016.076 |
0.315 |
|
| 2016 |
Yang JC, Popat S, Novello S, Groen HJ, Perol M, Felip E, Griesinger F, Reckamp KL, Lee J, Smit EF, Blakely CM, Akerley WL, Kim Y, Bazhenova L, Califano R, et al. TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. Journal of Clinical Oncology. 34: TPS9106-TPS9106. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9106 |
0.332 |
|
| 2016 |
Yang JC, Kim D, Kim S, Cho BC, Lee J, Ye X, Yin X, Yang Z, Jiang H, Ahn M. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. Journal of Clinical Oncology. 34: 9002-9002. DOI: 10.1200/Jco.2016.34.15_Suppl.9002 |
0.321 |
|
| 2015 |
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Jama Oncology. 1-8. PMID 26720423 DOI: 10.1001/Jamaoncol.2015.4921 |
0.344 |
|
| 2015 |
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372: 2018-28. PMID 25891174 DOI: 10.1056/Nejmoa1501824 |
0.31 |
|
| 2015 |
Park K, Lee J, Lee KH, Kim J, Min YJ, Cho JY, Han J, Kim B, Kim J, Lee DH, Kang JH, Cho EK, Jang I, Jung J, Kim H, et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). Journal of Clinical Oncology. 33: 8084-8084. DOI: 10.1200/Jco.2015.33.15_Suppl.8084 |
0.325 |
|
| 2015 |
Garon EB, Rizvi N, Hui R, Leighl NB, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens MA, Horn L, Carcereny E, Ahn M, Felip E, Lee J, Zhang J, et al. Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct104 |
0.308 |
|
| 2014 |
Han JJ, Kim YJ, Kim JW, Chang H, Lee JO, Lee KW, Jeong CW, Kim JH, Hong SK, Bang SM, Byun SS, Lee SE, Lee JS. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma. Tumori. 100: 439-45. PMID 25296594 DOI: 10.1700/1636.17906 |
0.306 |
|
| 2014 |
Kim JW, Kim SW, Tada K, Fukuda T, Lee JH, Lee JJ, Kwon JH, Bang SM, Kim I, Yoon SS, Lee JS, Park S. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Annals of Hematology. 93: 1345-51. PMID 24633661 DOI: 10.1007/S00277-014-2045-9 |
0.314 |
|
| 2014 |
Kim M, Chang H, Yang HC, Kim YJ, Lee CT, Lee JH, Jheon S, Kim K, Chung JH, Lee JS. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World Journal of Surgical Oncology. 12: 37. PMID 24520974 DOI: 10.1186/1477-7819-12-37 |
0.351 |
|
| 2014 |
Lee YG, Kwon JH, Kim I, Yoon SS, Lee JS, Park S. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide. European Journal of Haematology. 92: 478-84. PMID 24460733 DOI: 10.1111/Ejh.12274 |
0.308 |
|
| 2014 |
Kim YJ, Kim MJ, Cho YJ, Park JS, Kim JW, Chang H, Lee JO, Lee KW, Kim JH, Yoon HI, Bang SM, Lee JH, Lee CT, Lee JS. Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients. Medical Oncology (Northwood, London, England). 31: 847. PMID 24448977 DOI: 10.1007/S12032-014-0847-1 |
0.308 |
|
| 2014 |
Kim JW, Kim YJ, Lee KW, Chang H, Lee JO, Kim KI, Bang SM, Lee JS, Kim CH, Kim JH. The early discontinuation of palliative chemotherapy in older patients with cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 773-81. PMID 24287502 DOI: 10.1007/S00520-013-2033-Y |
0.332 |
|
| 2014 |
Havel L, Lee J, Lee KH, Bidoli P, Kim J, Ferry D, Kim Y, Losonczy G, Steele N, Woo IS, Forst L, Ma Y, Shelton MJ, Bologna F, Huber B, et al. E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8043-8043. DOI: 10.1200/Jco.2014.32.15_Suppl.8043 |
0.349 |
|
| 2014 |
Kim D, Lee DH, Kang JH, Park K, Han J, Lee J, Jang I, Kim H, Son J, Kim J. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology. 32: 8011-8011. DOI: 10.1200/Jco.2014.32.15_Suppl.8011 |
0.306 |
|
| 2014 |
Kim HS, Kim HS, Sun J, Ahn M, Park K, Kim H, Chung I, Lee J, Lee S, Lee KH, Kim DJ, Kim HR, Kim J, Cho BC. A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus. Journal of Clinical Oncology. 32: 4083-4083. DOI: 10.1200/Jco.2014.32.15_Suppl.4083 |
0.332 |
|
| 2014 |
Li RC, Saleem S, Zhen G, Cao W, Zhuang H, Lee J, Smith A, Altruda F, Tolosano E, Doré S. Errtum: Heme-hemopexin complex attenuates neuronal cell death and stroke damage (Journal of Cerebral Blood Flow and Metabolism (2014) 34 (736) DOI: 10.1038/jcbfm.2014.11) Journal of Cerebral Blood Flow and Metabolism. 34: 736. DOI: 10.1038/Jcbfm.2014.11 |
0.71 |
|
| 2013 |
Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer (Amsterdam, Netherlands). 82: 455-60. PMID 24075125 DOI: 10.1016/J.Lungcan.2013.08.027 |
0.354 |
|
| 2013 |
Kim JW, Chun EJ, Choi SI, Park do J, Kim HH, Bang SM, Kim MJ, Lee JH, Lee MS, Lee JO, Kim YJ, Kim JH, Lee JS, Lee KW. A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: an inquiry into the application of Western guidelines to Asian cancer patients. Plos One. 8: e61968. PMID 23613988 DOI: 10.1371/journal.pone.0061968 |
0.303 |
|
| 2013 |
Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH. Practical outcome of adjuvant folfox4 chemotherapy in elderly patients with stage iii colon cancer: Single-center study in korea Japanese Journal of Clinical Oncology. 43: 132-138. PMID 23204187 DOI: 10.1093/Jjco/Hys195 |
0.343 |
|
| 2013 |
Yang Y, Chang H, Lee J, Kim Y, Jheon S, Chung J. Prognostic value of epidermal growth factor receptor gene amplification in surgically resected non-adenocarcinoma lung cancer patients. Journal of Clinical Oncology. 31: e18553-e18553. DOI: 10.1200/Jco.2013.31.15_Suppl.E18553 |
0.347 |
|
| 2012 |
Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS, Lee JS. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer (Amsterdam, Netherlands). 76: 387-92. PMID 22186628 DOI: 10.1016/J.Lungcan.2011.11.022 |
0.362 |
|
| 2012 |
Park K, Tsai C, Ahn M, Yu C, Kim S, Sriuranpong V, Kuo HP, Lee J, Kang JH, Lin M, Geater SL, Chang G, Seetalarom K, So PFP, Lai R, et al. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7614 |
0.33 |
|
| 2012 |
Kim TM, Lee K, Oh D, Lee J, Im S, Kim D, Han S, Kim YJ, Kim T, Kim JH, Park K, Son J, Bang Y. A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 30: 3076-3076. DOI: 10.1200/Jco.2012.30.15_Suppl.3076 |
0.301 |
|
| 2012 |
Shin DY, Lee JO, Kim YJ, Park MS, Lee KW, Kim KI, Bang SM, Lee JS, Kim CH, Kim JH. Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment Journal of Geriatric Oncology. 3: 359-367. DOI: 10.1016/J.Jgo.2012.06.002 |
0.334 |
|
| 2011 |
Kim JW, Kim BS, Bang SM, Kim I, Kim DH, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, et al. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Annals of Hematology. 90: 1409-18. PMID 21468694 DOI: 10.1007/S00277-011-1227-Y |
0.313 |
|
| 2011 |
Kim YJ, Kim JH, Park MS, Lee KW, Kim KI, Bang SM, Lee JS, Kim CH. Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy Journal of Cancer Research and Clinical Oncology. 137: 839-847. PMID 20820804 DOI: 10.1007/S00432-010-0945-1 |
0.307 |
|
| 2010 |
Kim J, Kim B, Bang S, Kim I, Kim DH, Kim WS, Yang D, Lee J, Lee J, Kim JS, Sohn SK, Yhim H, Kwak J, Yoon S, Lee JS, et al. Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation Blood. 116: 3536-3536. DOI: 10.1182/Blood.V116.21.3536.3536 |
0.319 |
|
| 2010 |
Chang HJ, Lee K, Choi IS, Kim YJ, Kim JH, Bang S, Lee J. Abstract 2716: Tailored-dose capecitabine chemotherapy as adjuvant treatment in elderly colon cancer patients Cancer Research. 70: 2716-2716. DOI: 10.1158/1538-7445.Am10-2716 |
0.32 |
|
| 2009 |
Li RC, Saleem S, Zhen G, Cao W, Zhuang H, Lee J, Smith A, Altruda F, Tolosano E, Doré S. Heme-hemopexin complex attenuates neuronal cell death and stroke damage. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 29: 953-64. PMID 19277051 DOI: 10.1038/Jcbfm.2009.19 |
0.727 |
|
| 2009 |
Lee KW, Yi J, Choi IS, Kim JH, Bang SM, Kim DW, Im SA, Kim TY, Yoon SS, Lee JS, Bang YJ, Park S, Kim BK, Cho HI, Heo DS. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Annals of Hematology. 88: 829-38. PMID 19172274 DOI: 10.1007/S00277-008-0682-6 |
0.302 |
|
| 2009 |
Lee GW, Kang MH, Kim HG, Kang JH, Kim SH, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim HJ, Lee JS. Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer Cancer Chemotherapy and Pharmacology. 64: 385-390. PMID 19104817 DOI: 10.1007/S00280-008-0885-5 |
0.355 |
|
| 2008 |
Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Japanese Journal of Clinical Oncology. 39: 27-32. PMID 18952704 DOI: 10.1093/Jjco/Hyn118 |
0.31 |
|
| 2008 |
Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, Kim JH, Im SA, Kim TY, Lee JS, Bang YJ. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Japanese Journal of Clinical Oncology. 38: 589-95. PMID 18772169 DOI: 10.1093/Jjco/Hyn078 |
0.316 |
|
| 2008 |
Park H, Lee J, Chie E. Comparison of Chemotherapy Regimen in Preoperative Chemoradiation for Rectal Cancer International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.1735 |
0.301 |
|
| 2007 |
Choi IS, Oh DY, Kim BS, Lee KW, Kim JH, Lee JS. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 39: 99-103. PMID 19746224 DOI: 10.4143/Crt.2007.39.3.99 |
0.316 |
|
| 2007 |
Park K, Lee J, Wu Y, Zhang L, Cheng A, Siu-Kie-Au J, Voravud N, Muthalib A, Wahid MIA, Yang C. PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S464-S465. DOI: 10.1097/01.Jto.0000283408.85001.F3 |
0.317 |
|
| 2004 |
Lee G, Kang J, Kim S, Lee HY, Kim H, Lee W, Lee J, Hwang Y, Jang J, Lee J. A phase II trial of docetaxel and ifosfamide for patients with platinum-resistant or refractory non-small cell lung cancer in a salvage setting. Cancer Research and Treatment. 36: 287-292. PMID 20368817 DOI: 10.4143/Crt.2004.36.5.287 |
0.364 |
|
| Show low-probability matches. |